文献速递临床试验与 GCP真实世界研究与卫生经济

针对慢加急性肝衰竭入院后前28天的家庭多学科肝脏优化方案(LivR well):一项随机对照试验的研究方案

A home-based, multidisciplinary liver optimisation programme for the first 28 days after an admission for acute-on-chronic liver failure (LivR well): a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2022-09-05

本研究为在澳大利亚墨尔本多站点四级医疗服务机构开展的随机对照试验方案,计划招募符合EF-Clif标准的慢加急性肝衰竭患者120例和肝失代偿患者320例,分别按1:1随机分配至28天多学科家庭干预组或标准门诊照护组。慢加急性肝衰竭队列主要结局为28天死亡率,肝失代偿队列主要结局为30天再入院率,随访12周。

要点

  • 慢加急性肝衰竭患者28天无移植死亡率为33.9%。
  • 干预组接受护理、药学、物理治疗、营养、社会工作和神经精神科等多学科支持。
  • 可行性研究提示干预安全可接受,但需随机对照试验生成稳健结局。

核心结论

  • 本研究旨在通过家庭多学科肝脏优化方案改善慢加急性肝衰竭或肝失代偿患者入院后前28天的结局。
  • 可行性研究提示干预安全可接受,但需随机对照试验生成稳健结局。
  • 此类干预迫切需要对可行性、可重复性和可扩展性进行评估。

研究设计与样本

  • 研究方案为随机对照试验,在澳大利亚墨尔本多站点四级医疗服务机构的急诊科、住院部和门诊肝病诊所招募成人慢性肝病患者。
  • 符合EF-Clif标准的慢加急性肝衰竭患者120例和肝失代偿患者320例分别按1:1随机分配至28天多学科干预组或标准门诊照护组。
  • 慢加急性肝衰竭队列主要结局为28天死亡率,肝失代偿队列主要结局为30天再入院率,随访12周。
  • 将在招募达50%时进行中期分析,以考虑若干预优于对照则提前终止试验。
  • 将进行成本效果分析,并按转诊来源、非计划住院和合并COVID-19进行三项探索性亚组分析。

主要发现

  • 慢加急性肝衰竭患者28天无移植死亡率为33.9%。
  • 可行性研究提示干预安全可接受,并在小样本中提示临床改善。
  • 干预组包括护理、药学、物理治疗、营养、社会工作 and 神经精神科临床医生的支持。
  • 研究将评估肝病严重程度和生活质量的变化。
  • 研究将评估30天再入院和28天死亡率。

关键数值与推荐

  • 慢加急性肝衰竭队列主要结局为28天死亡率。
  • 肝失代偿队列主要结局为30天再入院率。
  • 慢加急性肝衰竭患者28天无移植死亡率为33.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 可行性研究样本量小。
  • 需要随机对照试验生成稳健结局。
  • 干预需要在不同医疗系统中评估可行性、可重复性和可扩展性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute-on-chronic liver failure (ACLF) represents a rising global healthcare burden, characterised by increasing prevalence among patients with decompensated cirrhosis who have a 28-day transplantation-free mortality of 33.9%. Due to disease complexity and a high prevalence of socio-economic disadvantage, there are deficits in quality of care and adherence to guideline-based treatment in this cohort. Compared to other chronic conditions such as heart failure, those with liver disease have reduced access to integrated ambulatory care services. The LivR Well programme is a multidisciplinary intervention aimed at improving 28-day mortality and reducing 30-day readmission through a home-based, liver optimisation programme implemented in the first 28 days after an admission with either ACLF or hepatic decompensation. Outcomes from our feasibility study suggest that the intervention is safe and acceptable to patients and carers. METHODS: We will recruit adult patients with chronic liver disease from the emergency departments, in-patient admissions, and an ambulatory liver clinic of a multi-site quaternary health service in Melbourne, Australia. A total of 120 patients meeting EF-Clif criteria will be recruited to the ACLF arm, and 320 patients to the hepatic decompensation arm. Participants in each cohort will be randomised to the intervention arm, a 28-day multidisciplinary programme or to standard ambulatory care in a 1:1 ratio. The intervention arm includes access to nursing, pharmacy, physiotherapy, dietetics, social work, and neuropsychiatry clinicians. For the ACLF cohort, the primary outcome is 28-day mortality. For the hepatic decompensation cohort, the primary outcome is 30-day re-admission. Secondary outcomes assess changes in liver disease severity and quality of life. An interim analysis will be performed at 50% recruitment to consider early cessation of the trial if the intervention is superior to the control, as suggested in our feasibility study. A cost-effectiveness analysis will be performed. Patients will be followed up for 12 weeks from randomisation. Three exploratory subgroup analyses will be conducted by (a) source of referral, (b) unplanned hospitalisation, and (c) concurrent COVID-19. The trial has been registered with the Australian New Zealand Clinical Trials Registry. DISCUSSION: This study implements a multidisciplinary intervention for ACLF patients with proven benefits in other chronic diseases with the addition of novel digital health tools to enable remote patient monitoring during the COVID-19 pandemic. Our feasibility study demonstrates safety and acceptability and suggests clinical improvement in a small sample size. An RCT is required to generate robust outcomes in this frail, high healthcare resource utilisation cohort with high readmission and mortality risk. Interventions such as LivR Well are urgently required but also need to be evaluated to ensure feasibility, replicability, and scalability across different healthcare systems. The implications of this trial include the generalisability of the programme for implementation across regional and urban centres. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12621001703897 . Registered on 13 December 2021. WHO Trial Registration Data Set. See Appendix 1.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ngu NL, Saxby E, Worland T, et al. A home-based, multidisciplinary liver optimisation programme for the first 28 days after an admission for acute-on-chronic liver failure (LivR well): a study protocol for a randomised controlled trial. Trials. 2022. PMID: 36064596. doi:10.1186/s13063-022-06679-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。